T. Rowe Price Investment Management
IGMS

T. Rowe Price Investment Management’s IGM Biosciences IGMS Stock Holding History

T. Rowe Price Investment Management’s Portfolio IGMS Stock Details IGMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-586,663
Closed -$13.3M – 554
2022
Q3 		$13.3M Buy
+586,663
New +$11.8M 0.01% 482

Other funds holding IGMS

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

T. Rowe Price Investment Management's IGMS Position: Q4 2022 in Review

T. Rowe Price Investment Management sold out of IGM Biosciences (IGMS) in Q4 2022, closing a stake of 586,663 shares — an estimated $13.3M sold.

T. Rowe Price Investment Management first reported a position in IGMS in Q3 2022 and held it in 1 quarter. The position peaked at $13.3M in Q3 2022. 82 funds tracked by Wall St. Rank hold IGMS as of Q4 2022.

  • T. Rowe Price Investment Management reported no remaining IGM Biosciences position as of Q4 2022 after selling out during the quarter.
  • T. Rowe Price Investment Management sold 586,663 IGM Biosciences shares in Q4 2022, an estimated $13.3M.
  • T. Rowe Price Investment Management first reported a position in IGM Biosciences in Q3 2022 and held it in 1 quarter.
  • T. Rowe Price Investment Management's IGM Biosciences position peaked at $13.3M in Q3 2022.
  • 82 funds tracked by Wall St. Rank held IGM Biosciences as of Q4 2022.

Based on T. Rowe Price Investment Management's 13F filing for Q4 2022, filed 14 Feb 2023.